Nigeria, Dec. 5 -- A new report by the Gates Foundation has revealed that long-acting HIV prevention tools, such as lenacapavir, the twice-yearly HIV-prevention injection, offer some of the strongest opportunities to drive infections and deaths towards zero in high-burden countries.

The 2025 Goalkeepers Report, released on Thursday, highlights lenacapavir's potential as a transformative HIV prevention option, particularly for women and adolescent girls who face barriers to using existing daily oral Pre-Exposure Prophylaxis (prep) due to stigma, adherence challenges, or inconsistent access to medication.

Recently, South Africa, Eswatini, and Zambia commenced the first rollout of the twice-yearly HIV-prevention injection, marking the init...